OM
Outset Medical, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.56
P/S
0.61
EV/EBITDA
-2.35
DCF Value
$-68.61
FCF Yield
-64.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
39.1%
Operating Margin
-55.6%
Net Margin
-68.3%
ROE
-55.0%
ROA
-30.9%
ROIC
-29.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $28.9M | $-19.5M | $-1.09 |
| FY 2025 | $119.5M | $-81.7M | $-5.37 |
| Q3 2025 | $29.4M | $-17.8M | $-1.00 |
| Q2 2025 | $31.4M | $-18.5M | $-1.04 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.96
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.